ozempic 1mg

Ozempic is a once-weekly subcutaneous injection containing semaglutide, a GLP-1 receptor agonist. It is manufactured by Novo Nordisk and primarily prescribed as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes. Beyond glycemic control, it significantly reduces the risk of major cardiovascular events (like heart attacks or strokes) and lowers the risk of chronic kidney disease progression in diabetic patients • Common Side Effects: The most widespread side effects are gastrointestinal, including nausea, vomiting, diarrhea, abdominal pain, and constipation. These are usually most noticeable when first starting or escalating a regimen.
• Weight Impact: While Ozempic is not officially approved as a primary weight-loss medication (Novo Nordisk markets a higher-dose version called Wegovy for that purpose), clinical trials show that type 2 diabetes patients taking semaglutide experience average weight reduction over several months.
• Serious Warnings: Ozempic is contraindicated in individuals with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious but rare long-term risks include acute pancreatitis, worsening diabetic retinopathy (vision changes), acute gallbladder disease, and severe allergic reactions